After five years of patent litigation, including two jury trials and an appeal before the US Court of Appeals for the Federal Circuit, Steptoe obtained a key district court victory for Sanofi and Regeneron over Amgen relating to their cholesterol-fighting biologic known as Praluent®. On August 28, the US District Court for the District of Delaware ruled in favor of Sanofi and Regeneron and found as a matter of law that three of Amgen’s asserted patent claims were invalid for lack of enablement. A jury had already found two other asserted patent claims invalid for lack of written description, meaning that Sanofi and Regeneron successfully invalidated all of Amgen’s asserted patent claims.
The Steptoe litigation team assisting Sanofi and Regeneron includes intellectual property partners John Molenda and Vishal Gupta; of counsel Bobby Greenfeld; associates Michael Flynn-O’Brien, Richard Praseuth, Ryann Muir, and David Feigenbaum; and law clerk Henry Ard.
The case has received widespread coverage in the biotech industry and legal media. Full coverage can be read at BioPharma Dive, Bloomberg Law, Endpoints News, EP Vantage, FiercePharma, Good Manufacturing Practice News, Law360, Life Sciences Intellectual Property Review, Pink Sheet, PM Live, Reuters, and XConomy.